Hoechst Pakistan Limited (PSX:HPL)

Market Cap	38.47B +24.5%
Revenue (ttm)	30.96B +15.7%
Net Income	2.90B +56.2%
EPS	300.69 +56.2%
Shares Out	9.64M
PE Ratio	13.27
Forward PE	n/a
Dividend	240.00 (6.02%)
Ex-Dividend Date	Apr 1, 2026

Volume	502
Average Volume	760
Open	3,988.20
Previous Close	3,987.51
Day's Range	3,988.00 - 4,010.00
52-Week Range	2,900.00 - 4,889.99
Beta	0.34
RSI	48.00
Earnings Date	Apr 22, 2026

About Hoechst Pakistan

Hoechst Pakistan Limited, together with its subsidiary, manufactures, sells, and trades in pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company offers allergy management, anti-diarrheals, antibiotics, antiemetic, cardiology, consumer healthcare, diabetes, neurology, and emergency care products under various brand names, as well as vaccines. It exports its products. The company was formerly known as Sanofi-Aventis Pakistan Limited and changed its name to Hoechst Pakistan Limited in September 2023. Hoechs...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 957
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HPL

Financial Performance

In 2025, Hoechst Pakistan's revenue was 30.96 billion, an increase of 15.73% compared to the previous year's 26.75 billion. Earnings were 2.90 billion, an increase of 56.16%.